Is Angi, Inc. overvalued or undervalued?

As of 28 November 2025, the valuation grade for Angi, Inc. has moved from fair to expensive, indicating a shift towards overvaluation. The company appears overvalued based on its P/E ratio of 16, which is higher than the industry average, and an EV to EBITDA ratio of 8.45, which suggests a premium compared to peers. Additionally, the Price to Book Value stands at 0.81, reflecting a relatively low valuation against its book value.
In comparison to its peers, Angi, Inc. has a P/E ratio of 14.77, while GoodRx Holdings, Inc. shows a much higher P/E of 31.76, indicating that Angi is not only overvalued but also less attractive than some competitors. The return comparison with the S&P 500 is not available, but the current valuation metrics reinforce the conclusion that Angi, Inc. is overvalued in the current market context.